AIM
ALDX icon

Acrospire Investment Management’s Aldeyra Therapeutics ALDX Stock Holding History

Acrospire Investment Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-442
Closed -$2K – 2143
2017
Q1 		$2K Buy
+442
New +$2.28K ﹤0.01% 2100

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Acrospire Investment Management's ALDX Position: Q2 2017 in Review

Acrospire Investment Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2017, closing a stake of 442 shares — an estimated $2K sold.

Acrospire Investment Management first reported a position in ALDX in Q1 2017 and held it in 1 quarter. The position peaked at $2K in Q1 2017. 26 funds tracked by Wall St. Rank hold ALDX as of Q2 2017.

  • Acrospire Investment Management reported no remaining Aldeyra Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 442 Aldeyra Therapeutics shares in Q2 2017, an estimated $2K.
  • Acrospire Investment Management first reported a position in Aldeyra Therapeutics in Q1 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Aldeyra Therapeutics position peaked at $2K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.